Follows adults with chronic myeloid leukemia taking asciminib in Korea
Observes safety and effectiveness of asciminib in Korean adults with chronic myeloid leukemia.
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Anyang-si, Bucheon-si, Gyeonggi-do, Incheon, Jeollanam, Pusan, Seoul, Suwon, Taegu, Uijeongbu-si, and Wŏnju, South KoreaSee the 11 sites
- Trial code
- Registry title
- Asciminib RMP Study
- Status
- Recruiting
- People taking part
- 600 people, planned
- Started
- 19 Jul 2023
- Expected to end
- 7 Jun 2030
- Type of study
- Observational
- Treatments tested
- Asciminib
- Record updated
- 20 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Ph+ chronic-phase chronic myeloid leukemia who are getting or about to get Scemblix (asciminib) under its approved label in Korea.
- Age
- 18 to 100 years
- Sex
- All sexes can join.
- Disease stage
- Ph+ chronic-phase chronic myeloid leukemia (Ph+ CP-CML).
- Earlier treatment
- Must be receiving or about to receive Scemblix according to the locally approved label.
- Biomarker or test result
- Ph+ (Philadelphia chromosome positive) leukemia.
Main reasons for not taking part
- Has a contraindication listed in the approved Scemblix label
- Is receiving or will receive any investigational medicine during the observation period
- Is not willing to give written informed consent
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label
- Patients who are willing to provide written informed consent prior to study enrollment
Who cannot take part
- Patients with contraindication according to locally approved label of Scemblix®
- Patients who receive or are going to receive any investigational medicine during the observation period
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in South Korea
- Anyang-si, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Bucheon-si, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Gyeonggi-do, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- IncheonHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- JeollanamHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- PusanHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Seoul, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Suwon, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- TaeguHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Uijeongbu-si, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Wŏnju, Gangwon-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
About the trial
What the trial wants to find out
This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.
The group in the trial
- Asciminib
Patients prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Post Approval Surveillance of Scemblix® (Asciminib) in Patients With Chronic Myeloid Leukemia (CML) in Korea
- Plain-language title
- Follows adults with chronic myeloid leukemia taking asciminib in KoreaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05943522, who can take part
- Record updated
- 20 April 2026